Zura Bio Ltd
No enriched coverage for $ZURA in the last 7 days.
No SEC Form 4 filings for $ZURA in the last 30 days.
See all $ZURA insider activity →Zura Bio (ZURA) reported Q2 results, completing two Phase 2 trials ahead of schedule. Tibulizumab is being tested for three indications, with cash reserves expected to last until 2028. Net loss widened to $26.3M due to increased R&D spending. Hedge fund ownership declined, and short interest remains high at 15.95%.
Zura Bio Ltd (ZURA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates • TibuSHIELD enrollment complete, exceeding initial enrollment target with 247 participants randomized in HS; topline data expected Q4 2026 • TibuSURE enrollment complete, exceeding i
The article highlights 10 growth stocks with increased insider ownership, using a Finviz screen and criteria including at least 20% compounded earnings growth over three years. It cites analyst actions and company updates for Sonida Senior Living (SNDA) and Zura Bio (ZURA), including SNDA price target raises to $48 and ZURA Phase 2 enrollment and $225.6M cash.
Recent ZURA coverage spans earnings, financial news and technology.
The enrollment milestones may boost short‑term optimism, but the expanding loss raises cash‑flow concerns.
Enrollment completion and a new Phase 2 indication expand near-term clinical catalysts, while cash runway through end-2028 reduces financing risk.
Clinical-trial enrollment completion and updated readouts can re-rate probability-weighted outcomes for tibulizumab programs.
Trial-enrollment progress and forward timelines support a bullish catalyst path, but the article provides no new clinical efficacy datapoint yet.
Enrollment completion plus a defined 4Q26 data trigger creates a clear near-to-mid-term catalyst calendar for ZURA.
AlphAI scores every news story that mentions ZURA with an AI model for sentiment and relevance, and aggregates insider trades from Zura Bio Ltd's SEC EDGAR Form 4 filings. Figures refresh continuously.
Zura Bio (ZURA) reported Q2 results, completing two Phase 2 trials ahead of schedule. Tibulizumab is being tested for three indications, with cash reserves expected to last until 2028. Net loss widened to $26.3M due to increased R&D spending. Hedge fund ownership declined, and short interest remains high at 15.95%.
2 min readZura Bio Ltd (ZURA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates • TibuSHIELD enrollment complete, exceeding initial enrollment target with 247 participants randomized in HS; topline data expected Q4 2026 • TibuSURE enrollment complete, exceeding i
4 min readThe article highlights 10 growth stocks with increased insider ownership, using a Finviz screen and criteria including at least 20% compounded earnings growth over three years. It cites analyst actions and company updates for Sonida Senior Living (SNDA) and Zura Bio (ZURA), including SNDA price target raises to $48 and ZURA Phase 2 enrollment and $225.6M cash.
7 min readZura Bio (NASDAQ:ZURA) is advancing tibulizumab. According to analyst Matt Phipps, the drug’s dual inhibition of T- and B-cell inflammatory pathways could improve outcomes in autoimmune diseases. Zura completed Phase 2 enrollment in TibuSHIELD for hidradenitis suppurativa, with topline data expected in Q4 2026; TibuSURE in 1H 2027. Phipps projects $2.3B peak HS sales (NPV $8.04/share) and William Blair projects $1.6B peak SSc sales (NPV $4.51/share). Zura reported $225.6M cash as of Mar 31, 2026
4 min readClear Street names five biotech stocks for 2H 2026 catalysts: MoonLake (MLTX) Buy, $70 target; Cullinan (CGEM) Buy, $46; Zura Bio (ZURA) Buy, $18; Arrivent (AVBP) Buy, $47; Protagonist (PTGX) Buy, $116. It cites planned clinical readouts and regulatory milestones, plus MLTX’s ~$200M offering and AVBP’s up to $250M ATM filing.
7 min readZura Bio Ltd (ZURA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 tm2618327d1_ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 ZURA BIO LIMITED 2023 EQUITY INCENTIVE PLAN (As Amended June 1, 2023 and June 17, 2026) 1. Purpose The purpose of this Zura Bio Limited 2023 Equity Incentive Plan (the “ Plan ”) is to promote and closely align the interes
3 min readThis SEC filing (SCHEDULE 13G/A) details an amended passive investment disclosure for Zura Bio Limited (ZURA) as of March 31, 2026. Suvretta Capital Management, LLC, Averill Master Fund, Ltd., and Aaron Cowen are identified as reporting persons, collectively holding 9.9% of Class A Ordinary Shares. The filing clarifies their beneficial ownership, voting, and dispositive powers, including details about pre-funded warrants and specific ownership percentages for each entity.
2 min read
